Editing Sumatriptan (section)

==History==
[[File:Sumatriptan vails 100 5509.jpg|thumb|Sumatriptan vials]]

In 1991, Glaxo received approval for sumatriptan, which was the first available [[triptan]].{{Citation needed|date=March 2025}}

In July 2009, the US [[Food and Drug Administration]] (FDA) approved a single-use [[jet injector]] formulation of sumatriptan. The device delivers a subcutaneous injection of sumatriptan, without the use of a needle. [[Autoinjector]]s with needles have been previously available in Europe and North America.<ref name=Brandes>{{cite journal | vauthors = Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, Linn L, Farr SJ | title = Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use | journal = Headache | volume = 49 | issue = 10 | pages = 1435–1444 | year = 2009 | pmid = 19849720 | doi = 10.1111/j.1526-4610.2009.01530.x | s2cid = 25696109 }}</ref>

Phase III studies with an [[iontophoretic]] [[transdermal patch]] (Zelrix/Zecuity) started in July 2008.<ref>{{ClinicalTrialsGov|NCT00724815|The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)}}</ref> This patch uses low [[voltage]] controlled by a pre-programmed [[Integrated circuit|microchip]] to deliver a single dose of sumatriptan through the skin within 30 minutes.<ref>{{cite web |url = http://www.nupathe.com/description.php?secid=3&subsecid=7#_ELECTRONIC_DRUG |title = SmartRelief -electronically assisted drug delivery (iontophoresis) |website = nupathe.com |access-date = 19 February 2018 |url-status = live |archive-url = https://web.archive.org/web/20160107062814/http://www.nupathe.com/description.php?secid=3&subsecid=7#_ELECTRONIC_DRUG |archive-date = 7 January 2016 |df = dmy-all }}</ref><ref>{{cite journal | vauthors = Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T | title = Zelrix: a novel transdermal formulation of sumatriptan | journal = Headache | volume = 49 | issue = 6 | pages = 817–825 | date = June 2009 | pmid = 19438727 | doi = 10.1111/j.1526-4610.2009.01437.x | s2cid = 205683188 | doi-access = free }}</ref> Zecuity was approved by the FDA in January 2013.<ref>{{cite web |url = http://ir.nupathe.com/press-releases/nupathe-s-zecuity-approved-by-the-fda-for-the-acut-nasdaq-path-975802NuPathe's |title = Zecuity Approved by the FDA for the Acute Treatment of Migraine |website = nupathe.com |access-date = 19 February 2018 |url-status = live |archive-url = https://web.archive.org/web/20160107062814/http://ir.nupathe.com/press-releases/nupathe-s-zecuity-approved-by-the-fda-for-the-acut-nasdaq-path-975802NuPathe's |archive-date = 7 January 2016 |df = dmy-all }}</ref> Sales of Zecuity have been stopped following reports of skin burns and irritation.<ref>{{cite web|url=http://www.fiercepharma.com/pharma/teva-pulls-migraine-patch-zecuity-reports-burning-scarring|title=Teva pulls migraine patch Zecuity on reports of burning, scarring |website=FiercePharma |date=13 June 2016 |access-date=10 April 2017|url-status=live|archive-url=https://web.archive.org/web/20170321022606/http://www.fiercepharma.com/pharma/teva-pulls-migraine-patch-zecuity-reports-burning-scarring|archive-date=21 March 2017}}</ref>